A 60-year-old postmenopausal woman with osteoporosis and a prior wrist fracture; which of the following is the most appropriate first-line pharmacologic treatment to reduce fracture risk?

A 60-year-old postmenopausal woman with osteoporosis and a prior wrist fracture; which of the following is the most appropriate first-line pharmacologic treatment to reduce fracture risk?

• A. Denosumab
• B. Teriparatide
• C. Alendronate
• D. Risedronate

Answer: (D)

The main idea here is that for postmenopausal osteoporosis with a prior fragility fracture, starting an antiresorptive medication that has proven to lower fracture risk is the standard first-line approach. Bisphosphonates are the most established option because they inhibit osteoclast-mediated bone resorption, which helps increase bone density and, crucially, reduces the risk of vertebral and nonvertebral fractures. Risedronate fits this role well. It is a bisphosphonate with strong evidence showing reductions in vertebral and nonvertebral fractures, including fractures of the wrist, which is precisely the type of fragility fracture this patient has experienced. It also offers convenient dosing options (often weekly) and a safety profile that is well understood. Denosumab can reduce fracture risk, but it is typically reserved for patients who cannot take oral bisphosphonates or have other specific considerations, and stopping denosumab can lead to a rebound loss of bone density. Teriparatide is an anabolic option used for very high-risk cases or after failure of antiresorptives, but it is more costly and involves daily injections, making it less suitable as initial therapy in a general high-risk postmenopausal patient. So, starting with a bisphosphonate like risedronate provides solid fracture-risk reduction with practical dosing and broad supportive evidence, making it the best first-line choice in this scenario. Ensure adequate calcium and vitamin D, and monitor with follow-up and DXA as appropriate.

The main idea here is that for postmenopausal osteoporosis with a prior fragility fracture, starting an antiresorptive medication that has proven to lower fracture risk is the standard first-line approach. Bisphosphonates are the most established option because they inhibit osteoclast-mediated bone resorption, which helps increase bone density and, crucially, reduces the risk of vertebral and nonvertebral fractures.

Risedronate fits this role well. It is a bisphosphonate with strong evidence showing reductions in vertebral and nonvertebral fractures, including fractures of the wrist, which is precisely the type of fragility fracture this patient has experienced. It also offers convenient dosing options (often weekly) and a safety profile that is well understood.

Denosumab can reduce fracture risk, but it is typically reserved for patients who cannot take oral bisphosphonates or have other specific considerations, and stopping denosumab can lead to a rebound loss of bone density. Teriparatide is an anabolic option used for very high-risk cases or after failure of antiresorptives, but it is more costly and involves daily injections, making it less suitable as initial therapy in a general high-risk postmenopausal patient.

So, starting with a bisphosphonate like risedronate provides solid fracture-risk reduction with practical dosing and broad supportive evidence, making it the best first-line choice in this scenario. Ensure adequate calcium and vitamin D, and monitor with follow-up and DXA as appropriate.